Literature DB >> 30658595

Correlation between Interleukin-17 gene polymorphism and osteoarthritis susceptibility in Han Chinese population.

Yuming Bai1,2, Shijun Gao3, Ying Liu4, Shengli Jin2, Haisen Zhang2, Ke Su2.   

Abstract

BACKGROUND: Interleukin-17 (IL-17), a pleiotropic cytokine, plays a significant role in the inflammatory diseases. By a pilot study with small population, IL-17 polymorphisms (IL-17A rs2275913 and IL-17F rs763780) showed a more potential risk factor in knee osteoarthritis (OA) in our recruited subjects. In the current study, the association between IL-17A rs2275913 and IL-17F rs763780and the risk of OA in a Chinese population is studied.
METHODS: The IL-17A rs2275913 and IL-17F rs763780 polymorphisms were determined in 594 knee OA cases and 576 healthy controls, using polymerase chain reaction-restriction fragment length polymorphism assay. The relationship between genotype distribution and disease risk, as well as OA severity was analyzed by Chi-square test and multivariate logistic regression.
RESULTS: The experimental results indicated that the polymorphism in IL-17 gene rs2275913 site were related to knee OA risk after the adjustment of BMI, sex, age, smoking and drinking status (AA vs. GG: odds ratio (OR), 1.411; 95% confidence interval (CI), 1.021-1.950; P = 0.040; A allele vs. G allele: OR, 1.192; P = 0.037; 95% CI, 1.012-1.404;). Similarly, subjects who are bearing the rs763780 variant genotypes (TC and CC) and C allele also had a higher susceptibility to knee OA compared with those who are bearing the TT genotype (TC vs. TT, OR: 1.312; P = 0.039; 95% CI: 1.017-1.692; CC vs. TT, OR: 2.812, P = 0.006, 95% CI: 1.338-5.909; C allele Vs. T allele, OR:1.413, P = 0.002, 95% CI:1.141-1.751). In the meantime, one high-risk haplotypes, AC (OR was 7.22, P < 0.01) was found. Both two polymorphisms do not correlated with OA severity based on Kellgren-Lawrence (K&L) scales. Finally, serum IL-17 levels of knee OA patients were greatly higher than those of controls (P = 0.001).
CONCLUSIONS: With the limited size sample, our study shows that IL-17 gene polymorphisms possibly related to the high-risk knee OA occurrence.

Entities:  

Keywords:  IL-17A; IL-17F; Inflammation; Osteoarthritis; Polymorphism

Mesh:

Substances:

Year:  2019        PMID: 30658595      PMCID: PMC6339292          DOI: 10.1186/s12881-018-0736-0

Source DB:  PubMed          Journal:  BMC Med Genet        ISSN: 1471-2350            Impact factor:   2.103


Background

Osteoarthritis (OA), is featured by diverse changes and cartilage breakdown in the subchondral bone, resulting in chronic pain, deformity, joint swelling, and whole joint abnormalities. However, the exact cause of OA remains unknown. According to previous studies, OA has a complicated pathogenesis due to the interaction with complex pathogenic factors, including mechanical, biochemical, genetic, endocrine, metabolic, and environmental factors [1-5]. Moreover, the bony outgrowths (osteophytes), inflammation of the synovial membrane, and its triggering catabolic and pro-inflammatory mediators such as prostaglandin E2, neuropeptides, cytokines, and nitric oxide are essential to OA formation [5-7]. It is estimated that 18% of females and 9.6% of males older than 60 years suffer from symptomatic OA worldwide [8-11]. Although OA is considered a non-inflammatory condition earlier, with in-depth research on its physiopathology, now it is widely accepted that synovial inflammation is a feature of OA, and characterized by immune cell infiltration and cytokine secretion [12]. Both Innate immune system activation [13] and T-cell mediated inflammatory pathway play central roles in disease development and progression [14]. IL-17 is essential to both the adaptive and innate immune systems. It has five confirmed receptors (IL-17RA-RD and SEF) and six members (IL-17A-F) [15, 16]. IL-17A and IL-17F are secreted by Th17 cells, which is a distinct lineage of CD4+ effector cells [17]. Moreover, IL-17, as a pro-inflammatory cytokine, can trigger the release of chemokines, cytokines, antimicrobial peptides, and matrix metalloproteinases from mesenchymal and myeloid cells [18]. Previous studies also demonstrate that IL-17 is expressed in synovial tissues, and could contribute to cartilage breakdown and synovial infiltration in OA by inducing the release of chemokines by chondrocytes [19] and augments nitric oxide production in OA cartilage via nuclear factor kappa B activation [20]. Studies have reported that genetic polymorphisms of IL-17 are related to the susceptibility of a scope of inflammation-related diseases including ulcerative colitis, gastric cancer, breast cancer, and rheumatoid arthritis [21-24]. Although there is no relative report about association of IL-17 polymorphism with OA in the publicly available Genome wide association study database, we still hypothesize that IL-17 is a potential risk factor for OA pathogenesis. The correlation between the polymorphisms of IL-17A and IL-17F and the risk of knee osteoarthritis among the Chinese population has not been reported. By a pilot study with small population, IL-17A rs2275913 and IL-17F rs763780 shows more potential risk factor in OA in our recruited subjects. The present study focusses on these two SNPs to investigate their relationship with OA morbidity and severity.

Methods

Subjects

With all criteria adhered to the Declaration of Helsinki, this study was permitted by the Ethics and Research Committee of the Central Hospital of Cangzhou City, China. All participants provided written informed consent with gender, age, weight and body mass index (BMI) included. All participants were older than 40 years. Out of the 594 patients diagnosed with primary knee OA, 576 age-matched healthy controls free from symptoms or signs of OA. Other types of arthritis or joint diseases were enrolled in this study. The criteria of the American College of Rheumatology was utilized in diagnosing knee OA [25], including primary OA with any symptom and radiographic sign of OA as per the Kellgren-Lawrence (K&L) scale (≥2 scale). Two independent examiners blind to the clinical data carried out the clinical examination and radiological assessment. The sex and age matched control subjects were free from personal or family history of OA. Other etiologies that cause knee diseases, such as inflammatory arthritis, post septic arthritis, and posttraumatic, developmental or skeletal dysplasia were not included.

Sample collection

Peripheral blood was collected by venipuncture from participants into EDTA tube for DNA isolation. In addition, the biochemical parameters of the serum were detected.

Genomic DNA isolation

DNA for genomic studies was extracted with commercial DNA Blood Mini Kit (QIAGEN, Hilden, Germany) from 200 μL of whole blood following the manufacturer’s instructions. DNA concentration was measured by spectrophotometry (NanoDrop 2000, Thermo Scientific) diluted to nearly 40 ng/μL.

DNA sequencing analysis

IL-17 copies in the samples were measured by PCR through amplification. The primers of SNP rs2275913 were as follows: forward 5’-ATTTCTGCCCTTCCCATTTT-3′ and reverse 5′- CCAGGAGTCATCGTTGTTT-3′. For SNP rs763780, the primers used were: forward 5’-GCAGAGCACTGGGTAAGGAG-3′ and reverse 5’-CTGCATCAATGCTCAAGGAA-3′. Sequencing was carried out by a Bio-Informatic company (Life technology, Shang Hai, China).

Serum IL-17A and IL-17F levels

Serum samples were collected from all patients and healthy subjects. The blood was allowed to clot for 30 min at 4 °C before centrifugation at 3000 rpm for 10 min at 4 °C. Total serum was separated and stored at − 20 °C until they were ready to be used. Sandwich ELISA was used to measure the concentrations of serum IL-17A and F following the manufacturer’s instructions. The intra-assay coefficients of variation came was set as 10%.

Statistical analysis

The demographic and clinical data were shown as Mean ± SD and compared among groups by the Student’s t-test. The genotype and allelic frequencies were assessed by Hardy-Weinberg equilibrium (HWE) and compared by Chi-square test and Fisher’s exact test by the online calculator tool (http://www.oege.org/software/hardy-weinberg.html). Association between the SNP and the OA risk was evaluated by calculating the Odds ratio (OR) and 95% confidence interval (CI) for the additive model, the dominant model, the recessive model by using SPSS 19.0 software (IBM SPSS, USA). P values < 0.05 were regarded as statistically significant.

Results

Features of two groups are consistent

The characteristics of the two groups of 594 knee OA patients and 576 control subjects were summarized in Table 1. The mean ages of the control group and knee OA group were 58.3 ± 9.6 and 59.5 ± 8.9 years respectively. There was no significant difference in mean age, sex, drinking and smoking status between these two groups, indicating subjective matching. The mean BMI of the OA group (26.2 ± 3.8) was greatly higher compared with that of the control group (24.6 ± 3.1) (P = 0.0478), which is consistent with previous findings that reported high BMI in OA [26, 27].
Table 1

Demographic characteristics of the study population

VariablesHealthy control (n = 576)Knee osteoarthritis patients (n = 594)P value
Age (mean ± SD)58.3 ± 9.659.5 ± 8.90.214
Gender0.517
Male174201
Female402393
Body mass index (kg/m2)24.6 ± 3.126.2 ± 3.80.0478
Smoking
Yes1832130.155
No393381
Drinking0.790
Yes6975
No507519
IL-17A concentration (x ± S, pg/mL)2.98 ± 0.143.91 ± 0.270.0325
IL-17F concentration (x ± S, pg/mL)104.5 ± 12.6142.8 ± 14.90.0249
Demographic characteristics of the study population

A allele of rs2275913 and C allele of rs763780 increase the risk of knee OA

The distribution of each allele and genotype is shown in Table 2. Both SNPs were within the Hardy-Weinberg equilibrium. In terms of the genotype and allele frequencies in rs2275913 polymorphism, there was a remarkably difference between OA patients and healthy controls, which was shown in Table 2. In addition, all subjects carrying AA genotype have significantly higher risks of OA compared with GG genotype (P < 0.05). The results revealed that subjects with the A allele were more likely to get knee OA compared with those bearing the G allele (OR, 1.1192; 95% CI, 1.012–1.404; p = 0.037). Further analysis demonstrated the higher risk of AA genotype and A allele mainly existed in female sub-population (P < 0.05), but not in male population (P > 0.05, Table 2).
Table 2

Distributions of IL-17 SNPs genotypes in each group and analyses of associations between these polymorphisms and knee OA risk

GenotypeOverall (N)Female (N)Male (N)
controlOAOR (95% CI) P controlOAOR (95% CI) P controlOAOR (95% CI) P
Additive model
rs2275913576594402393174201
GG2071891.001.0001451221.001.0062671.001.000
GA2652711.12 (0.864–1.452)0.4271841791.156 (0.842–1.587)0.37681921.051 (0.666–1.659)0.907
AA1041341.411 (1.021–1.950)0.0473921.498 (1.014–2.213)0.04831421.254 (0.703–2.236)0.466
Allele
G6796491.001.0004744231.001.002052261.001.000
A4735391.192 (1.012–1.404)0.0373303631.233 (1.011–1.503)0.0431431761.116 (0.835–1.493)0.460
rs763780
TT4113801.001.0002872461.001.0001241341.001.000
TC1551881.312 (1.017–1.692)0.0391081311.415 (1.042–1.923)0.02947571.122 (0.711–1.772)0.643
CC10262.812 (1.338–5.909)0.0067162.667 (1.079–6.588)0.0333103.085 (0.830–11.468)0.093
Allele
T9779481.001.0006826231.001.0002953251.001.000
C1752401.413 (1.141–1.751)0.0021221631.463 (1.129–1.894)0.00453771.319 (0.899–1.935)0.176
Dominant model
rs2275913
GG + GA4724601.000.0593293011.000.0891431591.000.514
AA1041341.322 (0.993–1.761)73921.378 (0.976–1.944)31421.219 (0.727–2.042)
rs763780
TT + TC5665681.000.013953771.000.0581711911.000.098
CC10262.591 (1.238–5.422)7162.395 (0.974–5.886)3102.984 (0.808–11.023)
Recessive model
rs2275913
GG2071891.000.1391451221.000.15462671.000.664
GA + AA3694051.202 (0.943–1.532)2572711.253 (0.933–1.684)1121341.107 (0.722–1.697)
rs763780
TT4113801.000.0072872461.000.011241341.000.372
TC + CC1652141.403 (1.096–1.795)1151471.491 (1.107–2.008)50671.240 (0.798–1.926)

OA osteoarthritis, OR odds ratio, CI confidence interval

Distributions of IL-17 SNPs genotypes in each group and analyses of associations between these polymorphisms and knee OA risk OA osteoarthritis, OR odds ratio, CI confidence interval With regards to the rs763780 polymorphism, similar results also observed. There was a significant difference in the genotype and allele frequencies between the two groups (knee OA patients and control subject groups), which was shown in Table 2. In addition, C allele rather than T allele can increase the risk of developing knee OA (Table 2). Further study also demonstrated that C allele more caused higher risk than in T allele in female subpopulation (P = 0.004). In the male population, the CC genotype and C allele did not induce significant higher risk for OA. Dominant and recessive model also demonstrated the similar results that A allele of rs2275913 and C allele of rs763780 increase the risk of knee OA.

IL-17 polymorphism is not related to OA severity

All included OA patients were over 2 Kellgren-Lawrence Grading Scales, and the typical CT-scan figures were showed per scale (Fig. 1). SNP distribution among healthy control (scale 0) and OA patients of different scale (2–4) were shown in Table 3. There is no significant difference among all the SNPs and alleles ranging from scale 2 to 4, suggesting no effect of IL-17 polymorphism on OA severity.
Fig. 1

Representive photos of different severity of knee OA based on Kellgren-Lawrence (K&L) scale (from stage 0 to stage 4)

Table 3

The association of different genotypes and alleles of various polymorphisms with the severity of knee OA

GenotypeNscale 2scale 3scale 4P value
rs22759135940.116
GG189635769
GA271789796
AA134294461
Allele0.057
G649204211234
A539136185218
rs7637800.272
TT380135141104
TC188556865
CC2661010
Allele0.077
T948325350273
C240678885
Representive photos of different severity of knee OA based on Kellgren-Lawrence (K&L) scale (from stage 0 to stage 4) The association of different genotypes and alleles of various polymorphisms with the severity of knee OA

Serum IL-17A/F levels are higher in OA patients

The median serum concentration of IL-17A was 2.98 ± 0.14 pg/ mL and 3.91 ± 0.27 pg/ mL in healthy controls and OA patients, respectively (Table 1). The serum levels of IL-17A in OA patients were higher than that of healthy controls (p = 0.0325). The serum levels of IL-17F in OA patients were also higher than that of healthy controls (P = 0.0249). However, when we further summarized the average serum concentration of IL-17A and IL-17F in each genotype, there was no significant difference among all three genotypes for these two SNPs (Table 4).
Table 4

The serum levels of IL-17A and IL-17F in the different genotypes

GenotypeIL-17A concentration (x ± S, pg/mL)IL-17F concentration (x ± S, pg/mL)P value
rs2275913 > 0.05
GG3.92 ± 0.48142.9 ± 45.6
GA3.76 ± 0.35134.5 ± 21.5
AA3.95 ± 0.50143.4 ± 32.3
rs763780 > 0.05
TT3.81 ± 0.44138.3 ± 43.4
TC3.75 ± 0.38143.1 ± 52.1
CC3.94 ± 0.39140.8 ± 43.8
The serum levels of IL-17A and IL-17F in the different genotypes

Discussion

Previous studies implicated that IL-17/IL23 pathway and TH17 cells play an important role in inflammation-related diseases [28], and several meta-analysis examined the relationship between IL-17A (rs2275913) and IL-17F (rs763780) gene polymorphisms and the risk of inflammatory diseases, including periodontitis, rheumatoid arthritis (RA), and inflammatory bowel disease, and all these documents demonstrate that IL-17 polymorphisms may increased the RA risk, but dependent with race and ethnic groups [29]. Beside RA, IL17A (rs2275913) polymorphism has been reported to be associated with the development of rheumatic heart disease in south Indian population [30], and a variant of IL17F (rs763780) may contribute to the development of necrotizing enterocolitis [31]. All these publications suggest that IL17 polymorphism may widely to be associated with immune mediated diseases. Although IL-17A and IL-17F have been reported to be associated with collagen-induced arthritis, and arthritis in experimental animal models [32], there is no study about relationship between rs2275913 (IL-17A SNP) and rs763780 (IL-17F SNP) with OA risk. Our study might be first time to investigate the involvement of IL-17 gene polymorphisms in knee OA and whether these are correlated with serum levels of IL-17. Up to date, we have yet to show whether these two SNPs affect the IL-17 secretion in the human plasma. But from data of Table 4, these two SNPs seem not influence the plasma concentration of IL-17A and IL-17F. Our results suggested that the IL-17A rs2275913 polymorphism has a significant impact on the risk of knee OA and that persons carrying the rs2275913 A allele are at a higher risk of developing knee OA as compared with those carrying the G allele. Additionally, rs763780 C allele, was also related to a greatly increased risk of developing knee OA. Further assessment of the effect of IL-17 polymorphisms on knee OA risk was stratified by sex, and showed a significant association in female patients’ subgroups. In spite of the positive relationship between rs2275913 and rs763780 polymorphisms and the risk of knee OA observed in this study, IL-17 serum levels had no great differences in allele subgroups. These data did not show any association between IL-17 serum levels and IL-17 polymorphisms in the present study, however, a higher serum concentration was found in overall patients when it was compared with the healthy control. The limitation is that we did not test the concentration of IL-17A and IL-17F in knee joint (mainly from knee articular cavity and synovial tissues) of each patient, and local concentration of IL-17 may be more important than systemic IL-17 in plasma. Therefore, it is possible that SNPs of IL-17 might cause alteration of the IL-17 concentration in knee joint microenvironment, including knee articular cavity and synovial tissues, further influence the risk of OA development. Patients carrying the A (rs2275913 G/A) and C (rs763780 T/C) alleles were related to increased risk for knee OA when compared to individuals who are carrying the wild-type alleles. Furthermore, we demonstrated that the correlation between the two polymorphisms under study and knee OA risk appeared significant among the female subjects; however, this evidence is just an association but not cause and effect. There is a possibility that this finding is as a result of the larger quantity of female subjects (n = 393) compared to the male subjects (n = 201), which may lead to a limited statistical power and robustness. This might also be attributed to other important factors related to women such as estrogen-relate effects and the fact that women are less exposed to tobacco smoking and heavy alcohol drinking [33, 34]. However, a larger sample size is needed to further investigate the underlying mechanisms of this association. Aside the small sample size, we acknowledge other limitations such as the study population. With the study population confined to the population of He Bei province, the findings may not apply to other population. It would of great significance if the role of IL-17 polymorphisms in patient susceptibility to knee OA from other ethnic population is studied. Also, the present research investigated only two SNPs in the IL-17 gene. It would be of more interest to define more SNPs and investigate their role in knee OA. More importantly, population stratification—allele frequency differences between cases and controls due to systematic ancestry differences—can cause spurious associations in disease studies, and possible false positive results [35]. Therefore, more detailed statistical analysis is needed to do to make results more accurately.

Conclusions

In conclusion, we have successfully demonstrated that functional polymorphisms of IL-17 are significantly related to the risk of knee OA. Also, the variant alleles rs2275913 AA and rs763780 CC were related to the increased risk of knee OA but not the wild-type alleles. Serum IL-17 levels significantly correlated with increased risk of knee OA which taking together might facilitate defining high risk subjects to prevent the initial development of knee OA.
  35 in total

1.  IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity.

Authors:  Mio Kawaguchi; Daisuke Takahashi; Nobuyuki Hizawa; Shintaro Suzuki; Satoshi Matsukura; Fumio Kokubu; Yukiko Maeda; Yoshinobu Fukui; Satoshi Konno; Shau-Ku Huang; Masaharu Nishimura; Mitsuru Adachi
Journal:  J Allergy Clin Immunol       Date:  2006-02-14       Impact factor: 10.793

2.  Meta-Analysis of Risk Association Between Interleukin-17A and F Gene Polymorphisms and Inflammatory Diseases.

Authors:  Ebrahim Eskandari-Nasab; Mehdi Moghadampour; Arezoo Tahmasebi
Journal:  J Interferon Cytokine Res       Date:  2017-02-10       Impact factor: 2.607

3.  Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage.

Authors:  M G Attur; R N Patel; S B Abramson; A R Amin
Journal:  Arthritis Rheum       Date:  1997-06

4.  Association study of single nucleotide polymorphisms of IL23R and IL17 in rheumatoid arthritis in the Algerian population.

Authors:  S Louahchi; I Allam; L Berkani; A Boucharef; A Abdesemed; N Khaldoun; A Nebbab; A Ladjouze; R Djidjik
Journal:  Acta Reumatol Port       Date:  2016 Apr-Jun       Impact factor: 1.290

5.  Association of single nucleotide polymorphisms of IL23R and IL17 with necrotizing enterocolitis in premature infants.

Authors:  Jiayi Tian; Yanjun Liu; Yanfang Jiang; Haohan Zhou; Tong Zhu; Xiaoqi Zhao; Liping Peng; Chaoying Yan
Journal:  Mol Cell Biochem       Date:  2017-02-21       Impact factor: 3.396

Review 6.  Genetic factors in OA pathogenesis.

Authors:  Kay Chapman; Ana M Valdes
Journal:  Bone       Date:  2011-12-08       Impact factor: 4.398

7.  Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.

Authors:  Harumichi Ishigame; Shigeru Kakuta; Takeshi Nagai; Motohiko Kadoki; Aya Nambu; Yutaka Komiyama; Noriyuki Fujikado; Yuko Tanahashi; Aoi Akitsu; Hayato Kotaki; Katsuko Sudo; Susumu Nakae; Chihiro Sasakawa; Yoichiro Iwakura
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

Review 8.  Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review.

Authors:  B J E de Lange-Brokaar; A Ioan-Facsinay; G J V M van Osch; A-M Zuurmond; J Schoones; R E M Toes; T W J Huizinga; M Kloppenburg
Journal:  Osteoarthritis Cartilage       Date:  2012-09-07       Impact factor: 6.576

9.  Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand.

Authors:  Gry B N Nordang; Marte K Viken; Jade E Hollis-Moffatt; Tony R Merriman; Øystein T Førre; Knut Helgetveit; Tore K Kvien; Benedicte A Lie
Journal:  Rheumatology (Oxford)       Date:  2009-02-10       Impact factor: 7.580

10.  Association between IL17 polymorphisms and risk of cervical cancer in Chinese women.

Authors:  Yi Quan; Bin Zhou; Yanyun Wang; Ruiqi Duan; Kana Wang; Qianqian Gao; Shaoqing Shi; Yaping Song; Lin Zhang; Mingrong Xi
Journal:  Clin Dev Immunol       Date:  2012-09-25
View more
  11 in total

1.  Val109Asp Polymorphism of the Omentin-1 Gene and Incidence of Knee Osteoarthritis in a Chinese Han Population: A Correlation Analysis.

Authors:  Ruofei Chen; Yaqin Zhang; Honggang Xu; Huaqing Hu; Mingwei Chen; Zongwen Shuai
Journal:  Drug Des Devel Ther       Date:  2021-12-21       Impact factor: 4.162

2.  IL-17 Facilitates VCAM-1 Production and Monocyte Adhesion in Osteoarthritis Synovial Fibroblasts by Suppressing miR-5701 Synthesis.

Authors:  Tsung-Ju Wu; Sunny Li-Yun Chang; Chih-Yang Lin; Chao-Yang Lai; Xiu-Yuan He; Chun-Hao Tsai; Chih-Yuan Ko; Yi-Chin Fong; Chen-Ming Su; Chih-Hsin Tang
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

3.  Application of network pharmacology and molecular docking to elucidate the potential mechanism of Eucommia ulmoides-Radix Achyranthis Bidentatae against osteoarthritis.

Authors:  Gong-Hui Jian; Bing-Zhu Su; Wen-Jia Zhou; Hui Xiong
Journal:  BioData Min       Date:  2020-08-28       Impact factor: 2.522

4.  Role of IL-17 gene polymorphisms in osteoarthritis: A meta-analysis based on observational studies.

Authors:  Hao-Yu Yang; Yu-Zhou Liu; Xin-Die Zhou; Yong Huang; Nan-Wei Xu
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

5.  Interleukin-17A Causes Osteoarthritis-Like Transcriptional Changes in Human Osteoarthritis-Derived Chondrocytes and Synovial Fibroblasts In Vitro.

Authors:  Jolet Y Mimpen; Mathew J Baldwin; Adam P Cribbs; Martin Philpott; Andrew J Carr; Stephanie G Dakin; Sarah J B Snelling
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

6.  Association between the polymorphism of IL-17A and IL-17F gene with knee osteoarthritis risk: a meta-analysis based on case-control studies.

Authors:  Feifan Lu; Pei Liu; Qidong Zhang; Weiguo Wang; Wanshou Guo
Journal:  J Orthop Surg Res       Date:  2019-12-16       Impact factor: 2.359

7.  The relationship between magnesium and osteoarthritis of knee: A MOOSE guided systematic review and meta-analysis.

Authors:  Zhiming Wu; Juguang Yang; Jiangtao Liu; Kai Lian
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

8.  An Evidence-Based Systematic Review of Human Knee Post-Traumatic Osteoarthritis (PTOA): Timeline of Clinical Presentation and Disease Markers, Comparison of Knee Joint PTOA Models and Early Disease Implications.

Authors:  Christine M Khella; Rojiar Asgarian; Judith M Horvath; Bernd Rolauffs; Melanie L Hart
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

Review 9.  The Link Between Inflammaging and Degenerative Joint Diseases.

Authors:  Elena Rezuș; Anca Cardoneanu; Alexandra Burlui; Andrei Luca; Cătălin Codreanu; Bogdan Ionel Tamba; Gabriela-Dumitrița Stanciu; Nicoleta Dima; Codruța Bădescu; Ciprian Rezuș
Journal:  Int J Mol Sci       Date:  2019-01-31       Impact factor: 5.923

Review 10.  An insight into osteoarthritis susceptibility: Integration of immunological and genetic background.

Authors:  Debora Stefik; Vladimir Vranic; Nemanja Ivkovic; Dzihan Abazovic; Dusan Maric; Danilo Vojvodic; Gordana Supic
Journal:  Bosn J Basic Med Sci       Date:  2021-04-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.